The strategic goal of the company is scientific research, development activities, and the implementation of new technologies. It aims to promote the development of innovative technologies focused on harmonizing the human factor in relationships with the natural environment, ensuring the natural life activities of society-nature subjects.
The company’s activities include
The scientific potential of the company’s participants is currently focused on developing major research areas, primarily addressing national-level issues and problems. These include increasing the efficiency of livestock production, rational use of water and land resources, natural minerals and exploitation of deposits, industrial waste disposal, and more.
To date, the company, under a licensing agreement and considering registered patents in the Republic of Armenia and the EAEU, has introduced the biologically active feed additive “Evrital” and the veterinary drug “Arivir” to the market. These products, based on numerous test results, aim for high consumption levels among large livestock companies, regardless of species restrictions, ensuring stable and growing production performance indicators in livestock product reproduction.
Considering the expanding global drinking water market and the critical role of water resources in their rational use and production of high-quality products as an export segment of Armenia’s economy, the company conducts independent research based on its own developed analysis methods. This research aims to identify, analyze, and summarize the existing legal and regulatory components of the issue to develop specific proposals for forming the most effective state-legal aspects to address this task.
In this context, the company’s specialists are developing a fundamentally new technological chain for water purification and iodization. In connection with this, a memorandum has been signed with EMART GROUP (which has the right to exploit an underwater aquifer well) to implement this technology in the water bottling process under the trademark FAWA.
As part of its research activities, the company, in collaboration with JSC “Scientific Center for Antiviral Drugs” in the Republic of Kazakhstan, is developing methods for treating diseases such as coronavirus infections, including coronavirus-bacterial conglomerates, mycoplasmal and bacterial pneumonia, and inflammatory reactive arthritis.
